QR код

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study

Abstract Background The study aimed to examine the direct medical cost and impact of tocilizumab (TOZ) versus adalimumab (ADM) and etanercept (ETC) on reducing the levels of two inflammatory markers (e.g., C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) among patients with rheumat...

Повний опис

Збережено в:
Автори: Areej S. Albahdal, Amjad M. Alotaibi, Miteb A. Alanazi, Norah Abanmy, Monira Alwhaibi, Yazed AlRuthia
Формат: Artigo
Мова:Inglês
Опубліковано: BMC 2024-02-01
Серія:Cost Effectiveness and Resource Allocation
Предмети:
Tocilizumab
Etanercept
Adalimumab
Arthritis
Rheumatoid
Cost analysis
Онлайн доступ:https://doi.org/10.1186/s12962-024-00522-7
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси